NICE gives Aubagio the nod

Share this article:

The UK's price watchdog NICE has approved Sanofi's oral MS medication Aubagio for adults with relapsing-remitting multiple sclerosis, which means the National Health Service will begin funding the drug within the next three months.

Wednesday's thumbs-up is a re-tread. NICE told Sanofi in September that Sanofi had to provide cost-effectiveness data that would indicate the drug deserves a space on the formulary compared to what's already on the market. The drug costs around $22,500 per patient per year in the UK.

Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.